Uptake of and factors associated with testing for sexually transmitted infections in community-based settings among youth in Zimbabwe: a mixed-methods study.
Journal
The Lancet. Child & adolescent health
ISSN: 2352-4650
Titre abrégé: Lancet Child Adolesc Health
Pays: England
ID NLM: 101712925
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
04
08
2020
revised:
28
09
2020
accepted:
07
10
2020
pubmed:
9
1
2021
medline:
20
2
2021
entrez:
8
1
2021
Statut:
ppublish
Résumé
The prevalence of sexually transmitted infections (STIs) among youth is high in sub-Saharan Africa. We investigated the uptake of testing for and prevalence of Chlamydia trachomatis (chlamydia) and Neisseria gonorrhoeae (gonorrhoea) infections among youth in community-based settings in Zimbabwe, and explored the facilitators and barriers to testing. This study was nested within a cluster randomised trial of community-based delivery of integrated HIV and sexual and reproductive health services for youth aged 16-24 years. Chlamydia and gonorrhoea testing via urine samples using the Xpert CT/NG test was offered in the four intervention clusters in Harare, Zimbabwe. Factors associated with testing uptake were investigated in a subset of participants (n=257) using hierarchical multivariate logistic regression. In-depth interviews with a separate purposively selected sample (n=26) explored facilitators and barriers to STI testing and partner notification and were analysed using thematic analysis. Between June 1, 2019, and Jan 31, 2020, there were 6200 attendances by 4440 participants (78·2% women, 21·8% men) median age 20·3 (IQR 17·9-22·8) years. 1478 participants had 1501 tests done, and 248 tests were positive and 1253 tests were negative for chlamydia or gonorrhoea, or both. STI test uptake was 33·3% (95% CI 31·9-34·7), increasing from 11·7% in June, 2019, to 37·1% in January, 2020. The prevalence of chlamydia or gonorrhoea, or both, was 16·5% (95% CI 14·7-18·5; 248 of 1501), with only seven participants (3%) showing symptoms. The overall yield of testing was 4·0% (95% CI 3·5-4·5; 248 of 6200). Uptake was associated with having symptoms (adjusted odds ratio [OR] 14·8, 95% CI 1·66-132·07) and negatively associated with being single (adjusted OR 0·33, 95% CI 0·13-0·84) or having a boyfriend or girlfriend (adjusted OR 0·19, 95% CI 0·087-0·43) compared with being married, and being a student compared with being employed (adjusted OR 0·26, 95% CI 0·10-0·68). Perceived risk and symptoms of STIs were motivators for testing whereas misinformation, anticipated stigma, and concern about confidentiality were barriers. The prevalence of chlamydia or gonorrhoea, or both, was high among youth but only a minority were symptomatic. Therefore most infections would remain untreated without access to STI testing. Provision of education, counselling, and confidentiality are essential to improve uptake and acceptability of STI testing. Wellcome Trust.
Sections du résumé
BACKGROUND
The prevalence of sexually transmitted infections (STIs) among youth is high in sub-Saharan Africa. We investigated the uptake of testing for and prevalence of Chlamydia trachomatis (chlamydia) and Neisseria gonorrhoeae (gonorrhoea) infections among youth in community-based settings in Zimbabwe, and explored the facilitators and barriers to testing.
METHODS
This study was nested within a cluster randomised trial of community-based delivery of integrated HIV and sexual and reproductive health services for youth aged 16-24 years. Chlamydia and gonorrhoea testing via urine samples using the Xpert CT/NG test was offered in the four intervention clusters in Harare, Zimbabwe. Factors associated with testing uptake were investigated in a subset of participants (n=257) using hierarchical multivariate logistic regression. In-depth interviews with a separate purposively selected sample (n=26) explored facilitators and barriers to STI testing and partner notification and were analysed using thematic analysis.
FINDINGS
Between June 1, 2019, and Jan 31, 2020, there were 6200 attendances by 4440 participants (78·2% women, 21·8% men) median age 20·3 (IQR 17·9-22·8) years. 1478 participants had 1501 tests done, and 248 tests were positive and 1253 tests were negative for chlamydia or gonorrhoea, or both. STI test uptake was 33·3% (95% CI 31·9-34·7), increasing from 11·7% in June, 2019, to 37·1% in January, 2020. The prevalence of chlamydia or gonorrhoea, or both, was 16·5% (95% CI 14·7-18·5; 248 of 1501), with only seven participants (3%) showing symptoms. The overall yield of testing was 4·0% (95% CI 3·5-4·5; 248 of 6200). Uptake was associated with having symptoms (adjusted odds ratio [OR] 14·8, 95% CI 1·66-132·07) and negatively associated with being single (adjusted OR 0·33, 95% CI 0·13-0·84) or having a boyfriend or girlfriend (adjusted OR 0·19, 95% CI 0·087-0·43) compared with being married, and being a student compared with being employed (adjusted OR 0·26, 95% CI 0·10-0·68). Perceived risk and symptoms of STIs were motivators for testing whereas misinformation, anticipated stigma, and concern about confidentiality were barriers.
INTERPRETATION
The prevalence of chlamydia or gonorrhoea, or both, was high among youth but only a minority were symptomatic. Therefore most infections would remain untreated without access to STI testing. Provision of education, counselling, and confidentiality are essential to improve uptake and acceptability of STI testing.
FUNDING
Wellcome Trust.
Identifiants
pubmed: 33417838
pii: S2352-4642(20)30335-7
doi: 10.1016/S2352-4642(20)30335-7
pmc: PMC7818532
pii:
doi:
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
122-132Subventions
Organisme : Wellcome Trust
ID : 206316/Z/17/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R010161/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/T040327/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 206316_Z_17_17
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Références
J Infect Dis. 2008 Aug 1;198(3):349-58
pubmed: 18588484
BMC Public Health. 2010 Jan 18;10:19
pubmed: 20082718
PLoS One. 2019 Sep 12;14(9):e0213224
pubmed: 31513584
Expert Rev Mol Diagn. 2014 Mar;14(2):135-7
pubmed: 24450867
Sex Transm Dis. 2018 Jun;45(6):422-428
pubmed: 29465674
BMC Public Health. 2018 Nov 13;18(1):1254
pubmed: 30424761
BMC Infect Dis. 2018 May 19;18(1):229
pubmed: 29778101
Int J STD AIDS. 2018 May;29(6):531-539
pubmed: 29198180
PLoS One. 2015 Apr 24;10(4):e0124310
pubmed: 25909508
BMC Infect Dis. 2011 Aug 05;11:211
pubmed: 21816113
Sex Transm Dis. 2014 Sep;41(9):564-9
pubmed: 25118973
Int J Epidemiol. 1997 Feb;26(1):224-7
pubmed: 9126524
Bull World Health Organ. 2019 Aug 1;97(8):548-562P
pubmed: 31384073
J Adolesc Health. 2016 Jul;59(1):7-16
pubmed: 27338664
Int J STD AIDS. 2019 Mar;30(3):292-303
pubmed: 30396318
Int J STD AIDS. 2018 Jul;29(8):806-824
pubmed: 29486628
PLoS One. 2018 Apr 24;13(4):e0196209
pubmed: 29689080
PLoS Med. 2018 Feb 27;15(2):e1002512
pubmed: 29485985
PLoS Med. 2018 Feb 27;15(2):e1002511
pubmed: 29485986
Sex Transm Infect. 2020 May;96(3):211-219
pubmed: 31221744
Transfus Med. 2016 Feb;26(1):63-6
pubmed: 26834072
PLoS One. 2013 Jul 12;8(7):e68359
pubmed: 23874598
Clin Microbiol Infect. 2010 Aug;16(8):1062-9
pubmed: 20670288
PLoS One. 2017 Jan 3;12(1):e0169388
pubmed: 28046104
BMJ Sex Reprod Health. 2020 Jul;46(3):192-199
pubmed: 31871133
Sex Transm Dis. 2018 Jan;45(1):56-60
pubmed: 29240635
J Public Health (Oxf). 2017 Jun 1;39(2):407-414
pubmed: 27222237